Zentalis Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule treatments for cancer, Zentalis focuses on targeted therapies for solid tumors. Its lead drug candidate, azenosertib (ZN-c3), is a WEE1 inhibitor designed to block a protein that helps cancer cells repair damaged DNA. The company is headquartered in San Diego, California.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Walters William T | 13G/APassive | 18.8% | 17.84M | Aug 19, 2026 |
| WALTERS GROUP | 13G/APassive | 18.8% | 17.84M | Aug 19, 2026 |
| Walters, Susan B. | 13G/APassive | 18.8% | 17.84M | Aug 19, 2026 |
| Barclays PLC | 13G/APassive | 3.17% | 2.26M | Aug 13, 2026 |
| BlackRock, Inc. | 13GPassive | 5.2% | 3.71M | Jul 30, 2026 |
| Squadron Master Fund LP | 13GPassive | 5.1% | 3.68M | Mar 3, 2026 |
| Squadron Capital Management LLC | 13GPassive | 5.1% | 3.68M | Mar 3, 2026 |
| Matthew Sesterhenn | 13GPassive | 5.1% | 3.68M | Mar 3, 2026 |
| William Blank | 13GPassive | 5.1% | 3.68M | Mar 3, 2026 |
| Matrix Capital Management Company, LP | 13D/AActivist | 0% | 0 | Jan 2, 2026 |